A5082720713- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Ubiquitin and proteasome pathways
- Medical Imaging Techniques and Applications
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Hematological disorders and diagnostics
- Cancer Mechanisms and Therapy
- Ovarian cancer diagnosis and treatment
Weill Cornell Medicine
2017-2024
Cornell University
2015-2024
Clinical Research Associates
2017-2024
TB Alliance
2023
New York Hospital Queens
2009-2021
NewYork–Presbyterian Hospital
2010-2021
Presbyterian Hospital
2009-2021
Charles University
2019
Lymphoma Research Foundation
2007-2017
Boston Children's Museum
2014
The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes survival proliferation CLL cells.We conducted a phase 1b-2 multicenter study to assess safety, efficacy, pharmacokinetics, pharmacodynamics ibrutinib (PCI-32765), first-in-class, oral covalent inhibitor BTK designed for B-cell cancers, patients...
Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are commonly treated immediately at diagnosis. Because data on observation, or "watch and wait," have not been previously reported, we analyzed the outcome deferred initial therapy.Inclusion criteria in this retrospective analysis were a diagnosis MCL between 1997 2007 known date first treatment. Hospital research charts reviewed for prognostic treatment-related information. Date death was derived from hospital...
Human babesiosis is a tickborne malaria-like illness that generally resolves without complication after administration of atovaquone and azithromycin or clindamycin quinine. Although patients experiencing unresponsive to standard antimicrobial therapy have been described, the pathogenesis, clinical course, optimal treatment regimen such cases remain uncertain.We compared immunologic status, 14 case who experienced morbidity death persistence Babesia microti infection, despite repeated...
The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) rituximab (R) patients with diffuse large B-cell lymphoma (DLBCL) mantle cell (MCL).Seventy-six subjects untreated DLBCL (n = 40) MCL 36) received CHOP every 21 days (CHOP-21) R at 0.7 mg/m(2) 4), 1.0 9), or 1.3 63) on 1 4 for six cycles.Median age was 63 years (range, 20 to 87), International...
Mantle-cell lymphoma is generally incurable. Initial treatment not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy.We conducted single-group, multicenter, phase 2 study induction maintenance phases. During the phase, was administered at dose of 20 mg daily on days 1 through 21...
This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin's lymphoma (NHL).Patients had NHL disease after at least one chemotherapy regimen. Epratuzumab was administered intravenously 120 to 1,000 mg/m2 over 30 60 minutes weekly for four treatments.Fifty-five received were assessable safety; 51 response. Patients heavily pretreated (50% prior regimens)...
The hallmark of chronic myelocytic leukemia is the presence Philadelphia chromosome (Ph1). In recent studies, we obtained data that strongly suggested involvement an oncogene, c-abl, in this type leukemia. This normally located on 9, translocated to 22 as a result Ph1 translocation. addition, identified region 22, breakpoint cluster (bcr), which contains chromosomal all patients with who are positive for Ph1. Recent studies have bcr part gene truncated consequence deleted could be replaced...
This study is an integrated efficacy analysis of the five clinical trials tositumomab and iodine-131 in patients with relapsed or refractory low-grade, follicular, transformed low-grade non-Hodgkin's lymphoma (NHL) that resulted regulatory approval by US Food Drug Administration.This included 250 patients. Patients received a single course tositumomab. Responses were assessed independent panel radiologists oncologists.Response rates ranged from 47% to 68%; complete response 20% 38%. With...
Abstract Purpose: We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin’s lymphoma. Experimental Design: Epratuzumab was administered once weekly for 4 weeks at 120-1000-mg/m2 doses to 56 [most (n = 35) diffuse large B-cell lymphoma]. Results: Patients were heavily pretreated (median, prior therapies), 25% received high-dose chemotherapy stem...
Abstract BACKGROUND The accuracy of fluorodeoxyglucose positron emission tomography (FDG‐PET; dual‐head camera with attenuation correction) and Ga‐67 scintigraphy was compared to identify disease sites in patients Hodgkin (HD) intermediate high‐grade non‐Hodgkin lymphoma (NHL) at initial diagnosis or clinical recurrence. METHODS Fifty‐one contemporaneous FDG‐PET scintigraphies were performed on NHL (35 grade, 3 high grade) HD (13 patients). Sites correlated a site‐by‐site basis images....
Early prediction of response to therapy may offer the potential identify patients who will benefit from standard conventional therapy. The objective this study was determine predictive value FDG-PET as an early indicator after 1 cycle chemotherapy for progression-free survival (PFS) in diffuse large cell lymphoma (DLCL) and classic Hodgkin disease (HD).FDG-PET performed before, cycle, completion 47 patients. were followed with a median follow-up 21 months (range, 3-47 months). PFS compared...
This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.Eighty-two patients (median age, 64 years; 79% stage III/IV, one to nine prior treatments) received four once-weekly doses of 80 750 mg/m(2) veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, immunogenicity.Veltuzumab was well tolerated,...
Abstract Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractory MZL treated prior rituximab (RTX) or rituximab-based chemoimmunotherapy (RTX-CIT). We report final analysis median follow-up 33.1 months (range: 1.4-44.6). Overall response rate (ORR) was 58%; duration (DOR) 27.6 (95% confidence interval...